Glucotrack Completes First Human Trial of Novel Implantable Blood Glucose Monitor
核心洞察
Glucotrack successfully completed its first-in-human clinical study of a continuous blood glucose monitor implanted in the subclavian vein, with no serious adverse events reported.
The innovative device is designed for direct blood glucose measurement and offers potential three-year longevity without requiring external components, marking a significant advance in diabetes monitoring.
The four-day hospital study involving six diabetes patients demonstrated successful sensor placement and removal procedures, validating the safety profile of the implantable monitoring system.
Glucotrack, Inc. (Nasdaq: GCTK) has achieved a significant milestone in diabetes care with the successful completion of its first human clinical study of an implantable continuous blood glucose monitor (CBGM). The groundbreaking device, placed in the subclavian vein, represents a potential paradigm shift in glucose monitoring technology by measuring blood glucose levels directly rather than through interstitial fluid.
Safety and Procedural Success
The prospective single-arm study, conducted over four days in a hospital setting, focused primarily on evaluating the safety and procedural aspects of the CBGM sensor lead. Six participants with diabetes mellitus (搜索) requiring intensive insulin therapy underwent the trial. The study met its primary endpoint, with no procedure or device-related serious adverse events reported during the implantation period and through seven days post-removal.
"We are thrilled with the results of this first in human clinical study, which establishes safety of the placement, usage and removal of the CBGM sensor lead," said Paul V. Goode, PhD, President & Chief Executive Officer of Glucotrack. "While neither the study nor prototype system was designed to evaluate sensor accuracy, the system performed as expected with similar accuracy results as previously seen in our animal studies."
Innovative Technology Design
The CBGM system consists of a sensor lead placed intravascularly through a percutaneous procedure and connected to a prototype sensor electronics component positioned on the skin. Interventional cardiologists successfully performed both placement and removal procedures, demonstrating the feasibility of the surgical approach.
The technology's distinctive features include:
- Direct blood glucose measurement capability
- Planned three-year sensor longevity
- No permanent external components
- Minimal calibration requirements
Expert Perspective
David Klonoff, MD, Clinical Professor of Medicine at University of California, San Francisco and Editor-in-Chief of the Journal of Diabetes Science and Technology, offered his assessment: "The successful completion of this first in human study with no serious adverse events is encouraging. The study suggests that this approach could offer another alternative for continuously monitoring glucose levels in diabetes, and I look forward to seeing this technology advance into long-term clinical trials."
Future Development Path
This initial safety study marks a crucial step toward developing a less intrusive glucose monitoring solution for people with diabetes. The positive results support further development and testing of the technology, with future studies likely to focus on long-term performance and accuracy metrics.
The successful completion of this first human trial positions Glucotrack's CBGM as a potentially transformative technology in diabetes management, offering the promise of continuous, accurate blood glucose monitoring with reduced patient burden compared to current solutions.